Mytide Therapeutics is Discovery Tools (Healthcare) in United States that focus on biochemistry technology focus business. Founded in 2018. They cover business area such as developer, (BioFAB) technology, synthetic biomolecule, machine learning-base biochemistry technology focus, development, life-save biological therapeutic, user, serious illness, metabolic condition, cancer, inflammatory disorder.
2018
( 6 years old in 2024 )
Biochemistry Technology Focus
-
451 D Street
Suite 707
Boston, MA 02210
United States
Private
developer(BioFAB) technologysynthetic biomoleculemachine learning-base biochemistry technology focusdevelopmentlife-save biological therapeuticuserserious illnessmetabolic conditioncancerinflammatory disorder
* We use standard office opening hours in near Mytide Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Mytide Therapeutics is Discovery Tools (Healthcare) business from United States that founded in 2018 (6 years old in 2024), Mytide Therapeutics business is focusing on Biochemistry Technology Focus.
Mytide Therapeutics headquarter office and corporate office address is located in 451 D Street Suite 707 Boston, MA 02210 United States.
Mytide Therapeutics was founded in United States.
In 2024, Mytide Therapeutics is currently focus on biochemistry technology focus sector.
Above is snippet of Google Trends for "biochemistry technology focus" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Mytide Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
